

"The collaboration between BlueRock and the McEwen Institute at UHN will continue to greatly enrich and expedite the development of regenerative therapy approaches for cardiovascular disease," said Dr. Protze. "I am thrilled to have the

opportunity to develop BlueRock's unique *Cell+Gene* therapy platform and translate its capabilities to new treatments."

Additionally, BlueRock will increase the amount of funding and the breadth of sponsored research programs with Dr. Gordon Keller, PhD, Director, McEwen Stem Cell Institute, Dr. Protze and Dr. Michael Laflamme, MD, PhD, Principal Investigator. This funding will enable BlueRock to advance native and engineered cell programs in cardiac indications as well as additional areas.

BlueRock Therapeutics is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock's *Cell+Gene* platform harnesses the power of cells for new medicines across neurology, cardiology and autoimmune indications. BlueRock's cell differentiation technology recapitulates the cell's developmental biology to produce native cell therapies which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock was founded in 2016 by Versant Ventures and capitalized with one of the largest-ever Series A financings in biotech history by Bayer AG and Versant.